NEW YORK (GenomeWeb News) – Avanticell Science said yesterday that it will head a consortium that includes Giltech and Culzean Medical Devices in developing three-dimensional cell-based assay systems for drug discovery research.
Avanticell specializes in cell culture products and services, Culzean Medical Devices designs and makes implantable medical products, and Giltech makes biomaterials and biodegradable products.
The two-year, £1 million ($2 million) project is being co-funded by the Technology Strategy Board, an entity set up by the Scottish government to promote technological innovation.
The companies will work together to “put living cells into a three-dimensional scaffold to create this new generation of three-dimensional cell-based assays,” the company said. Current cell-based assays are limited because they use conventional flat layers of cell cultures and three-dimensional cell cultures are “much more likely” to resemble human cells, it added.
“The project will result in the next generation of cell-based assays, accelerating and reducing the cost of new drug development to treat life-threatening diseases such as cancer,” Avanticell CEO Jo Oliver said in a statement.